We are committed to participating in as many existing IBD trials as possible to provide the best treatment opportunities for our patients.
Our goal is to contribute to the research that will one day find a cure for IBD, and in the meantime, to help our patients live more fulfilling, symptom-free lives.
Active Crohn's clinical trials
-
Rizankizumab (anti-IL 23)
An open label extension study enrolling moderate to severe Crohn’s disease patients that have failed one or more of the following: oral or local steroids; systemic steroids; immunomodulators; and/or biologic therapy
-
Rizankizumab (anti-IL 23)
A study enrolling moderate to severe Crohn’s disease patients that have failed one or more biologic therapy
-
Upadactinib (anti-Jak 1)
A study enrolling moderate to severe active Crohn's disease patients who have inadequately responded or are intolerant of prior biologic treatment
-
Oral Ozanimod (S1P1 and S1P5 agonist)
Phase 3 study of oral small molecule for moderate to severe active Crohn's disease
-
Stelara (anti-IL 12/23)
A Phase 3b study enrolling moderate to severely active Crohn’s disease patients for intravenous re-induction therapy with Ustekinumab
Early diagnosis/treatment of Crohn's
-
Vedolizumab IV, Adalimumab SC, and oral Methotrexate
An open label, triple therapy, phase 4 study for early treatment of Crohn’s disease
For patients with moderate to severe Crohn's or fistulizing Crohn's patients
-
Guselkumab (anti-IL 23)
A phase 2/3 study enrolling moderate to severe Crohn’s disease patients or fistulizing Crohn’s disease patients, with past colitis, ileitis, or ileocolitis
Active Ulcerative Colitis clinical trials
-
Risankizumab (anti-IL 23)
A study enrolling moderate to severe active ulcerative colitis patients who have failed a prior biologic treatment
-
Upadacitinib (anti-Jak 1)
A study enrolling moderate to severe ulcerative colitis patients that failed one or more biologic therapy
-
Guselkumab (anti-IL 23)
A Phase 2b/3 study of the efficacy and safety of Guselkumab in participants with moderately to severely active ulcerative colitis
Miscellaneous trials
-
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease